Verrica Pharmaceuticals Inc. (VRCA)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 12 | 9 | 5 | 8 | 36 | 30 | 25 |
| Operating profit | $m | -12 | -28 | ||||||
| Net profit | $m | -45 | -35 | -24 | -67 | -77 | -18 | -31 | -22 |
| EPS reported | $ | -1.68 | -1.74 | ||||||
| Operating cashflow per share | $ | -1.65 | -0.63 | ||||||
| Capex per share | $ | 0.00 | 0.00 | ||||||
| FCF per share | $ | -1.65 | -0.63 | ||||||
| Free cash flow | $m | -18 | -13 | ||||||
| Net debt | $m | -30 | -11 | ||||||
| Book value equity | $m | 25 | - | ||||||
| Book value per share | $ | 2.32 | 0.20 | ||||||
| Number of shares | m | 10.65 | 21.31 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 3.58 | 25.57 | ||||||
| P/S LTM | x | 2.49 | 2.92 | ||||||
| P/FCF LTM | x | -5.02 | -6.63 | ||||||
| EV/EBITDA LTM | x | -6.41 | -2.23 | ||||||
| EV/Sales LTM | x | 1.69 | 1.51 | ||||||
| Earnings Yield LTM | % | -20.21% | -28.31% | ||||||
| FCF Yield | % | -19.91% | -15.08% | ||||||
| Quality | |||||||||
| ROE | % | -72.29% | -444.44% | ||||||
| ROIC | % | -37.97% | -2.07% | ||||||
| Operating margin | % | -33.56% | -92.78% | ||||||
| Gross margin | % | +90.33% | +85.89% | ||||||
| FCF/Sales | % | -49.55% | -44.02% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +370.22% | +300.75% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -10.81 | -7.37 | ||||||
| Net Debt/EBITDA | x | 3.05 | 0.35 | ||||||
| EBIT/Net interest | x | -1.54 | -7.54 | ||||||
| Net debt/market cap | % | 0.00% | +1.55% | ||||||
| Net debt/Equity | x | -1.22 | - | ||||||
| Gross debt/equity | x | 0.07 | - | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma and other dermatological oncology indications. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum and common warts in Japan; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for use in malignant and pre-malignant dermatological indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Verrica Pharmaceuticals Inc. (VRCA)
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma and other dermatological oncology indications. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum and common warts in Japan; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for use in malignant and pre-malignant dermatological indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free